Researchers created a tool capable of comprehensively mapping crucial interactions underlying drug efficacy in one superfamily of cell receptors. One in every three FDA-approved drugs targets a single ...
A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center Androgen receptor pathway ...
AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a phase 2 trial. The Big Pharma ...